Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Year	2023	2022	2021	2020	2019
Net Income	-133.82	-121.76	-79	-36.17	46.38
Depreciation & Amortization	2.37	2.97	3.33	3.64	3.26
Share-Based Compensation	28.22	26.97	20.99	19.58	19.23
Other Operating Activities	0.08	7.03	-15.33	20.04	2.55
Operating Cash Flow	-103.15	-84.78	-70	7.09	71.42
Operating Cash Flow Growth	-	-	-	-90.08%	144.41%
Capital Expenditures	-9.06	-2.13	-0.75	-1.45	-5.42
Change in Investments	-44.52	57.02	37.74	21.28	-81.25
Investing Cash Flow	-53.58	54.9	36.99	19.83	-86.66
Share Issuance / Repurchase	2.21	21.26	3.61	10.48	6.85
Debt Issued / Paid	-0.33	0	0	0	-0.09
Other Financing Activities	196.24	-1.23	-0.53	-1.5	-4.19
Financing Cash Flow	198.13	20.03	3.08	8.98	2.57
Net Cash Flow	41.39	-9.85	-29.93	35.9	-12.67
Free Cash Flow	-112.21	-86.91	-70.75	5.64	66
Free Cash Flow Growth	-	-	-	-91.45%	151.54%
Free Cash Flow Margin	-141.67%	-100.87%	-72.88%	4.61%	32.16%
Free Cash Flow Per Share	-5.35	-4.22	-3.51	0.28	3.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).